

AMENDED CLAIMS

Claims 1-15 (cancelled).

- 5     16.     (Original) A transdermal patch, comprising  
a pharmaceutical composition, which comprises:  
a stabilized botulinum toxin; and  
an enhancing agent that facilitates transdermal administration of  
the botulinum toxin in a bioactive form to a subdermal target site  
10           of a human patient without being administered to the patient's  
circulatory system; and  
an adhesive disposed on one side of the transdermal patch to  
removably secure the patch to the patient's skin.
- 15     17.     (Original) The transdermal patch of claim 16, wherein the adhesive is  
disposed around a depot containing the pharmaceutical  
composition.
- 20     18.     (Original) The transdermal patch of claim 16, further comprising a  
plurality of needles extending from one side of the patch that is  
applied to the skin, wherein the needles extend from the patch to  
project through the stratum corneum of the skin without rupturing a  
blood vessel.
- 25     19.     (Original) The transdermal patch of claim 18, wherein the botulinum  
toxin is provided in a depot in the patch so that pressure applied to  
the patch causes botulinum toxin to be directed through the  
needles and under the stratum corneum.
- 30     20.     (Original) The transdermal patch of claim 16, wherein the botulinum  
toxin is provided in a dry state in a plurality of wells, each of the  
wells covered by a membrane that is dissolvable with a fluid, and  
wherein the enhancing agent mixes with the botulinum toxin as the

membrane over a well dissolves so that the absorption of the botulinum toxin is enhanced.

21. (Original) The transdermal patch of claim 16, wherein the botulinum  
5 toxin is botulinum toxin type A.

Claims 22-35 (cancelled).